Background
Crohn's and Colitis, ulcerative colitis, UC
DISEASE, ULCERATIVE COLITIS
Part of the data in this manuscript was previously presented at the 14th Congress of European Crohn's and Colitis Organisation (ECCO), Copenhagen, Denmark.Patients with ulcerative colitis (UC) often report impaired health-related quality of life (HRQoL). Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of UC. In addition to previous demonstrations of improved clinical measures (e.g., Mayo score), tofacitinib has been shown to improve HRQoL in patients with UC. This analysis explored the interrelationships among tofacitinib treatment, HRQoL, and disease activity (measured using Mayo subscores) using mediation modeling.